Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$434.2 million.

  • Zevra Therapeutics' Retained Earnings rose 753.3% to -$434.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$434.2 million, marking a year-over-year increase of 753.3%. This contributed to the annual value of -$505.3 million for FY2024, which is 2639.24% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Retained Earnings stood at -$434.2 million, which was up 753.3% from -$433.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Retained Earnings registered a high of -$262.6 million during Q2 2021, and its lowest value of -$508.4 million during Q1 2025.
  • In the last 5 years, Zevra Therapeutics' Retained Earnings had a median value of -$369.5 million in 2023 and averaged -$375.9 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 3269.86% in 2022, then skyrocketed by 753.3% in 2025.
  • Over the past 5 years, Zevra Therapeutics' Retained Earnings (Quarter) stood at -$267.0 million in 2021, then plummeted by 32.47% to -$353.7 million in 2022, then dropped by 13.02% to -$399.8 million in 2023, then decreased by 26.39% to -$505.3 million in 2024, then grew by 14.06% to -$434.2 million in 2025.
  • Its last three reported values are -$434.2 million in Q3 2025, -$433.7 million for Q2 2025, and -$508.4 million during Q1 2025.